Bacteria engineered to reduce hyperphenylalaninemia
Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
1. A genetically engineered bacterium for metabolizing phenylalanine comprising:
a) one or more heterologous gene(s) encoding a phenylalanine ammonia lyase (PAL), wherein the one or more gene(s) encoding the PAL is operably linked to a promoter that is not in nature associated with the one or more gene(s) encoding the PAL, said promoter directly or indirectly induced under low-oxygen or anaerobic conditions;
b) one or more heterologous gene(s) encoding a phenylalanine transporter, wherein the one or more gene(s) encoding the phenylalanine transporter is operably linked to a promoter that is not in nature associated with the one or more gene(s) encoding the phenylalanine transporter, said promoter directly or indirectly induced under low-oxygen or anaerobic conditions; and
c) one or more heterologous gene(s) encoding an L-amino acid deaminase (LAAD), wherein the one or more gene(s) encoding the LAAD is operably linked to an inducible promoter that is not in nature associated with the one or more gene(s) encoding the LAAD,
wherein the bacterium expresses: the gene(s) encoding PAL under conditions that induce the promoter operably linked to the gene(s) encoding PAL; the gene(s) encoding phenylalanine transporter under conditions that induce the promoter operably linked to the gene(s) encoding phenylalanin transporter; the gene(s) encoding LAAD under conditions that include the promoter operably linked to the gene(s) encoding LAAD;
and wherein the bacterium is Escherichia coli strain Nissle.
2. The bacterium of claim 1 , wherein the promoter operably linked to the gene(s) encoding a PAL and the promoter operably linked to the gene(s) encoding a phenylalanine transporter are separate copies of the same promoter.
3. The bacterium of claim 1 , wherein the promoter directly or indirectly induced under low-oxygen or anaerobic conditions is selected from the group consisting of an FNR-responsive promoter, an ANR-responsive promoter, and a DNR-responsive promoter.
4. The bacterium of claim 1 , wherein the promoter operably linked to the gene(s) encoding a LAAD is directly or indirectly induced by an environmental factor that is not naturally present in a mammalian gut.
5. The bacterium of claim 1 , wherein the gene(s) encoding a phenylalanine transporter is located on a chromosome in the bacterium.
6. The bacterium of claim 1 , wherein the gene(s) encoding a PAL is located on a plasmid in the bacterium.
7. The bacterium of claim 1 , wherein the gene(s) encoding a PAL is located on a chromosome in the bacterium.
8. The bacterium of claim 1 , wherein the gene(s) encoding the phenylalanine transporter, the gene(s) encoding a PAL, and the gene(s) encoding a LAAD are located on a chromosome in the bacterium.
9. The bacterium of claim 1 , wherein the PAL is from Anabaena variabilis (PAL1) or from Photorhabdus luminescens (PAL3).
10. The bacterium of claim 1 , wherein the phenylalanine transporter is PheP.
11. The bacterium of claim 1 , wherein the bacterium is an auxotroph in diaminopimelic acid or an enzyme in the thymidine biosynthetic pathway.
12. A pharmaceutically acceptable composition comprising the bacterium of claim 1 ; and a pharmaceutically acceptable carrier.
13. The bacterium of claim 1 , wherein the promoter operably linked to the gene(s) encoding a PAL and the promoter operably linked to the gene(s) encoding a phenylalanine transporter are different promoters.
14. The bacterium of claim 1 , wherein the bacterium comprises 3-5 copies of a PAL gene, 2 copies of a phenylalanine transporter gene, and 1 copy of a LAAD gene.